EGFR突變肺癌一線治療新思路,創新口服雙靶藥顯獨特優勢( 二 )


參考文獻:Apatinib plus gefitinib as first-line treatment in advanced EGFR-mutant non-small cell lung cancer: the phase III ACTIVE study (CTONG1706). J Thorac Oncol;
本文為***作者原創 , 未經授權不得轉載

推薦閱讀